Using multiple therapies together can be a more effective approach to treating cancer. Unlike many single therapies, to which tumors can develop resistance, combination therapies can target cancer from several different angles and overcome tumor resistance. To that end, Dr. Bellone is exploring the effectiveness of one such combination―consisting of checkpoint inhibition, adoptive cell transfer (ACT), and tumor necrosis factor (TNF)―against mouse models of melanoma and prostate cancer. His initial results are very promising, as the triple combination treatment greatly increased survival. Next, he plans to determine how these therapies affect tumors throughout treatment, which will hopefully reveal the mechanisms that enable effective anti-tumor responses and which must be maintained to ensure tumor elimination. Hopefully, this information will help improve therapeutic approaches for patients with advanced, tough-to-treat cancers.
Projects and Grants
Combining adoptive T cell therapy to tumor vessel targeting and checkpoint blockade for cancer therapy
Fondazione Centro San Raffaele (Italy) | Melanoma, Prostate Cancer | 2014
¡Hagamos correr la voz sobre la inmunoterapia! Haga clic para compartir esta página con su comunidad.